Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives.
Papillary thyroid carcinoma
Thyroglobulin
Ultrasound
Journal
European thyroid journal
ISSN: 2235-0640
Titre abrégé: Eur Thyroid J
Pays: England
ID NLM: 101604579
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
08
2018
revised:
21
09
2018
entrez:
26
2
2019
pubmed:
26
2
2019
medline:
26
2
2019
Statut:
ppublish
Résumé
Periodic ultrasonography (US) examination is recommended in many patients with papillary thyroid carcinoma (PTC) after treatment with radioactive iodine (RAI), but recurrences are confirmed in few cases. This study determined whether the indication of US in the first years after treatment with RAI can be selective when postoperative US and posttherapy whole-body scanning (RxWBS) ruled out persistent neck disease. This was a prospective study. Two hundred and fifty-four patients with PTC (242 of intermediate risk) undergoing thyroidectomy and RAI, who had no apparent disease at the time of initial therapy (including negative postoperative US and RxWBS), were studied. The patients were followed up for 5 years after treatment with RAI by annual US. At the end of 5 years, 47 patients (18.5%) had at least one suspicious US, but neck recurrence was confirmed in only 4 patients (1.5% of all patients and 8.5% of those with suspicious US). The remaining cases were considered false-positives. US did not reveal disease in the first or second year after treatment with RAI in any patient. In the third, fourth, and fifth year after treatment with RAI, considering only patients with unstimulated Tg < 1 ng/mL in these assessments, US revealed disease in 0, 1 (0.4%), and 1 (0.4%) patient, respectively. The results suggest that low- or intermediate-risk patients with PTC without persistent disease after thyroidectomy (including negative postoperative US and RxWBS) do not require repeat US examination in the first two years after treatment with RAI. In the following years until the fifth year, US can be restricted to patients with Tg ≥1 ng/mL.
Sections du résumé
BACKGROUND
BACKGROUND
Periodic ultrasonography (US) examination is recommended in many patients with papillary thyroid carcinoma (PTC) after treatment with radioactive iodine (RAI), but recurrences are confirmed in few cases. This study determined whether the indication of US in the first years after treatment with RAI can be selective when postoperative US and posttherapy whole-body scanning (RxWBS) ruled out persistent neck disease.
METHODS
METHODS
This was a prospective study. Two hundred and fifty-four patients with PTC (242 of intermediate risk) undergoing thyroidectomy and RAI, who had no apparent disease at the time of initial therapy (including negative postoperative US and RxWBS), were studied. The patients were followed up for 5 years after treatment with RAI by annual US.
RESULTS
RESULTS
At the end of 5 years, 47 patients (18.5%) had at least one suspicious US, but neck recurrence was confirmed in only 4 patients (1.5% of all patients and 8.5% of those with suspicious US). The remaining cases were considered false-positives. US did not reveal disease in the first or second year after treatment with RAI in any patient. In the third, fourth, and fifth year after treatment with RAI, considering only patients with unstimulated Tg < 1 ng/mL in these assessments, US revealed disease in 0, 1 (0.4%), and 1 (0.4%) patient, respectively.
CONCLUSION
CONCLUSIONS
The results suggest that low- or intermediate-risk patients with PTC without persistent disease after thyroidectomy (including negative postoperative US and RxWBS) do not require repeat US examination in the first two years after treatment with RAI. In the following years until the fifth year, US can be restricted to patients with Tg ≥1 ng/mL.
Identifiants
pubmed: 30800640
doi: 10.1159/000493978
pii: etj-0008-0041
pmc: PMC6381900
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41-45Références
J Clin Endocrinol Metab. 2000 Jan;85(1):175-8
pubmed: 10634383
Laryngoscope. 2005 Feb;115(2):264-7
pubmed: 15689747
J Clin Endocrinol Metab. 2005 Oct;90(10):5723-9
pubmed: 16030160
J Ultrasound Med. 2005 Oct;24(10):1385-9
pubmed: 16179622
J Clin Endocrinol Metab. 2013 Feb;98(2):636-42
pubmed: 23293334
Endocr Pract. 2014 Apr;20(4):293-8
pubmed: 24246348
Eur J Endocrinol. 2014 Jun;170(6):837-46
pubmed: 24659355
Eur Thyroid J. 2013 Sep;2(3):147-59
pubmed: 24847448
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Eur Thyroid J. 2015 Dec;4(4):239-45
pubmed: 26835427
J Clin Endocrinol Metab. 2017 Mar 1;102(3):893-902
pubmed: 27929713
Thyroid. 2017 Jul;27(7):908-914
pubmed: 28446060
Thyroid. 2018 Jun;28(6):722-728
pubmed: 29665748
Clin Endocrinol (Oxf). 2018 Jul;89(1):100-109
pubmed: 29672893
J Endocrinol Invest. 2018 Jul;41(7):849-876
pubmed: 29729004
Thyroid. 2018 Aug;28(8):997-1003
pubmed: 29845894